NasdaqCM - Nasdaq Real Time Price USD

ChromaDex Corporation (CDXC)

5.30

-0.19

(-3.46%)

At close: December 23 at 4:00:01 PM EST

3 US Growth Companies With High Insider Ownership Expecting Up To 119% Earnings Growth

As the U.S. stock market navigates a landscape marked by cautious optimism following a benign inflation reading, investors are closely monitoring potential volatility amid ongoing economic developments and policy decisions. In this context, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those closest to the business and may offer robust earnings potential despite broader market uncertainties.

Simply Wall St. 3 days ago

ROOT

CDXC
-3.46%
GENI
Exploring December 2024's US Undervalued Small Caps With Insider Buying

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and projected earnings growth of 15% per annum in the coming years. In this context, identifying stocks that are potentially undervalued can be crucial for investors seeking opportunities amidst fluctuating market conditions, particularly when insider buying suggests confidence from those closest to the company.

Simply Wall St. 4 days ago

TLRY

LMB

CDXC
-3.46%
Even though ChromaDex (NASDAQ:CDXC) has lost US$73m market cap in last 7 days, shareholders are still up 389% over 1 year

It's been a soft week for ChromaDex Corporation ( NASDAQ:CDXC ) shares, which are down 13%. But that isn't a problem...

Simply Wall St. 14 days ago

CDXC
-3.46%
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

LOS ANGELES, December 03, 2024--ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large.

Business Wire 20 days ago

CDXC
-3.46%
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?

ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks last month

CDXC
-3.46%
JAZZ
3 US Stocks Estimated To Be Trading At Discounts Ranging From 13% To 41%

In the midst of geopolitical tensions and fluctuating market indices, the U.S. stock market is experiencing a cautious sentiment as investors react to recent earnings reports and global developments. Despite these uncertainties, opportunities may arise for discerning investors who focus on identifying stocks that are potentially undervalued, offering a chance to invest in companies trading at significant discounts relative to their intrinsic value.

Simply Wall St. last month

CDXC
-3.46%
VZIO

BOW
3 US Growth Companies With Strong Insider Confidence

As the U.S. stock market experiences a sluggish stretch following a significant post-election rally, investors are closely monitoring Federal Reserve Chair Jerome Powell's comments on the "sometimes-bumpy path" to achieving inflation targets. In this environment, growth companies with high insider ownership can signal strong confidence from those who know the business best, offering potential resilience amidst market fluctuations.

Simply Wall St. last month

VCTR

CDXC
-3.46%
TOST
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement

LOS ANGELES, November 14, 2024--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is the hero ingredient in Longevity.Technology’s inaugural supplement called Longevity.Technology® LONGEVITY. Designed to support a healthier, longer life, the supplement includes Niagen, the gold standard ingredient for enhancing NAD+ leve

Business Wire last month

CDXC
-3.46%
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?

Does ChromaDex (CDXC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks last month

CDXC
-3.46%
5 Stocks With Recent Price Strength to Tap Wall Street Rally

Investors target stocks that are witnessing a bull run. Some of the stocks seeing price strength are CDXC, SEZL, TILE, BGC, CORT.

Zacks last month

CORT

CDXC
-3.46%
TILE
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

LOS ANGELES, November 07, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely ac

Business Wire last month

CDXC
-3.46%
Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality

ChromaDex Corporation's ( NASDAQ:CDXC ) strong earnings report was rewarded with a positive stock price move. Our...

Simply Wall St. last month

CDXC
-3.46%
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?

ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks last month

CDXC
-3.46%
MDXG
ChromaDex Third Quarter 2024 Earnings: Beats Expectations

ChromaDex ( NASDAQ:CDXC ) Third Quarter 2024 Results Key Financial Results Revenue: US$25.6m (up 31% from 3Q 2023). Net...

Simply Wall St. last month

CDXC
-3.46%
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

ChromaDex Corp (CDXC) reports a 31% revenue increase and outlines plans for further growth despite market challenges.

GuruFocus.com last month

CDXC
-3.46%
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 100% and 7.93%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CDXC
-3.46%
ChromaDex: Q3 Earnings Snapshot

LOS ANGELES (AP) — ChromaDex Inc. CDXC) on Thursday reported third-quarter net income of $1.9 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Los Angeles-based company said it had profit of 2 cents.

Associated Press Finance last month

CDXC
-3.46%
ChromaDex Corporation Reports Third Quarter 2024 Financial Results

LOS ANGELES, October 31, 2024--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024.

Business Wire last month

CDXC
-3.46%
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect

On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline.

Zacks last month

CDXC
-3.46%
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

LOS ANGELES, October 28, 2024--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday

Business Wire last month

CDXC
-3.46%

Performance Overview

Return	CDXC	S&P 500
YTD	+270.63%	+25.25%
1-Year	+265.52%	+25.65%
3-Year	+28.95%	+27.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ChromaDex Corporation (CDXC)

3 US Growth Companies With High Insider Ownership Expecting Up To 119% Earnings Growth

Exploring December 2024's US Undervalued Small Caps With Insider Buying

Even though ChromaDex (NASDAQ:CDXC) has lost US$73m market cap in last 7 days, shareholders are still up 389% over 1 year

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?

3 US Stocks Estimated To Be Trading At Discounts Ranging From 13% To 41%

3 US Growth Companies With Strong Insider Confidence

ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement

What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?

5 Stocks With Recent Price Strength to Tap Wall Street Rally

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality

ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?

ChromaDex Third Quarter 2024 Earnings: Beats Expectations

ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates

ChromaDex: Q3 Earnings Snapshot

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Performance Overview